United Therapeutics Corp (UTHR) Tops Q2 EPS Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $607.85 +1.09%
Financial Fact:
Income from continuing operations before income taxes: 239.1M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Income from continuing operations before income taxes: 239.1M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
United Therapeutics Corp (NASDAQ: UTHR) reported Q2 EPS of $1.49, $0.96 better than the analyst estimate of $0.53. Revenue for the quarter came in at $183.75 million versus the consensus estimate of $180.84 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- United Therapeutics Corp. (UTHR) PT Raised to $768 at BTIG
- CS Disco, Inc (LAW) Misses Q3 EPS by 6c; offers guidance
- United Therapeutics pays $525M to eliminate ralinepag royalty to Pfizer
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
